FindTrial
Sign In

Colestipol

DRUG6 trials

Sponsors

University of Washington, National Heart, Lung, and Blood Institute (NHLBI), Tuscaloosa Research & Education Advancement Corporation, Brigham and Women's Hospital, Derrick Scott Robertson

Conditions

Arterial Occlusive DiseasesAtherosclerosisCardiovascular DiseasesCarotid Artery DiseasesCerebral ArteriosclerosisCerebrovascular DisordersCoronary ArteriosclerosisCoronary Disease

Phase 1

Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride
TerminatedNCT02263547
Derrick Scott RobertsonHealthy Volunteers, Teriflunomide Elimination
Start: 2015-03-31End: 2016-06-30Updated: 2020-04-03

Phase 2

Sorbent Therapy of the Cutaneous Porphyrias
CompletedNCT01422915
Brigham and Women's HospitalErythropoietic Protoporphyria
Start: 2011-05-31End: 2012-03-31Updated: 2017-04-25
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
CompletedNCT02400476
Puma Biotechnology, Inc.Early Stage HER2+ Breast Cancer
Start: 2015-02-28End: 2021-04-22Updated: 2022-05-06

Phase 3

Familial Atherosclerosis Treatment Study
CompletedNCT00000512
University of WashingtonCardiovascular Diseases, Coronary Arteriosclerosis, Coronary Disease +2
Start: 1984-01-31End: 1989-08-31Updated: 2015-12-03
Cholesterol-Lowering Atherosclerosis Study (CLAS)
CompletedNCT00000599
National Heart, Lung, and Blood Institute (NHLBI)Arterial Occlusive Diseases, Atherosclerosis, Cardiovascular Diseases +7
Start: 1980-06-30End: 1994-11-30Updated: 2013-12-13

Phase 4

A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction
CompletedNCT00203476
Tuscaloosa Research & Education Advancement CorporationHypercholesterolemia, Hyperlipidemia
Start: 2005-05-31End: 2008-01-31Updated: 2014-08-12

Related Papers

Preclinical and clinical evaluation through serial colonoscopic evaluation of neratinib‐induced diarrhea in <scp>HER2</scp>‐positive breast cancer—A pilot study
Physiological Reports2024-08-015 citations
Abstract PO1-17-08: Post-approval treatment patterns and tolerability of neratinib in HER2+ early-stage breast cancer
Cancer Research2024-05-02
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer.
2022-12-1416 citations
Abstract P5-18-02: Final findings from the CONTROL trial of diarrheal prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer
Cancer Research2022-02-152 citations
Abstract P2-13-21: Improved central nervous system outcomes in patients with early-stage HER2-positive breast cancer who receive neratinib for the recommended duration: Findings from the phase 3 ExteNET trial
Cancer Research2022-02-151 citations
Association between treatment duration and overall survival in early-stage HER2+ breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial.
Journal of Clinical Oncology2021-05-206 citations
Dose escalation for mitigating diarrhea: Ranked tolerability assessment of anti-diarrheal regimens in patients receiving neratinib for early-stage breast cancer.
Journal of Clinical Oncology2021-05-203 citations
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Journal of Clinical Oncology2020-07-17586 citations
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.
2020-05-2576 citations
Abstract P5-14-03: Effect of prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2-positive early-stage breast cancer: Phase II CONTROL trial
Cancer Research2020-02-153 citations
Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Phase II CONTROL trial.
Journal of Clinical Oncology2019-05-2012 citations
Abstract P4-07-08: Budesonide and loperamide do not impact the cytotoxicity of neratinib or HER2-directed monoclonal antibodies in HER2+ breast cancer cell lines
Cancer Research2019-02-151 citations
Abstract P2-13-03: The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in HER2+ early-stage breast cancer: Analyses from the ExteNET and CONTROL trials
Cancer Research2019-02-151 citations
Abstract P6-03-02: Budesonide and colesevelam reduce neratinib-induced diarrhea in a rat model
Cancer Research2019-02-15
Abstract P3-14-01: Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients with HER2+ early-stage breast cancer: The CONTROL trial
Cancer Research2018-02-1514 citations
Abstract CT128: Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients (pts) with HER2+ early-stage breast cancer (eBC): the CONTROL trial
Cancer Research2017-07-0120 citations
Abstract P2-11-03: Incidence and severity of diarrhea with neratinib + intensive loperamide prophylaxis in patients (pts) with HER2+ early-stage breast cancer (EBC): Interim analysis from the multicenter, open-label, phase II control trial
Cancer Research2017-02-155 citations